Q1 2026 Earnings Preview
Key Questions
What are Wall Street's expectations for AbbVie's Q1 2026 EPS and revenue?
Wall Street anticipates Q1 EPS of $2.64-2.69, representing a 9% increase, and revenue of $14.78-15 billion, up 11%. These figures account for Humira's decline being offset by growth in Skyrizi, Rinvoq, and Botox.
How has AbbVie's stock typically performed after earnings reports?
ABBV shares have risen in the immediate aftermath of 6 out of 12 previous earnings reports. On average, the stock has moved down -0.2% on day 1 post-earnings.
When are AbbVie's Q1 2026 earnings expected, and what should investors watch for?
Earnings are imminent around April 27. Investors should prepare for potential volatility following the report.
Wall Street eyes Q1 EPS $2.64-2.69 (+9%), rev $14.78-15B (+11%); Humira plunge offset by Skyrizi/Rinvoq growth, Botox up. Post-earnings pattern: up 6/12 times, avg -0.2% day 1. Earnings imminent (~Apr 27), potential volatility post-report.
Sources (2)
Updated Apr 27, 2026